Takahiro Seki

Dr. Takahiro Seki

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2013 in Science
Verified
Journal Article
Closed access
PDF file
DMDaniel Martinez Molina
Daniel Martinez Molina
RJRozbeh Jafari
Rozbeh Jafari
MIMarina Ignatushchenko
Marina Ignatushchenko
TSTakahiro Seki
Takahiro Seki
ELE. Andreas Larsson
E. Andreas Larsson
PNPär Nordlund
Pär Nordlund
Drug Targeting: Drug efficacy depends on the extent of binding to a cellular target (often a protein) with adverse effects caused by excessive target binding or by off-target binding. Engagement of a target protein inside cells is influenced by the effective drug concentration and by factors that regulate the protein conformation, making it difficult to predict efficacy based on in vitro affinity studies. Martinez Molina et al. (p. 84 ) took advantage of the shift in protein thermal stability caused by drug binding to directly monitor target protein-drug interactions in cells. The method was used to monitor drug target engagement in cancer cells and in mouse livers and kidneys.

1 April 2009 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Jun FangJun Fang
Jun Fang
TSTakahiro Seki
Takahiro Seki
HMHiroshi Maeda
Hiroshi Maeda

7 September 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KHKayoko Hosaka
Kayoko Hosaka
YYYunlong Yang
Yunlong Yang
TSTakahiro Seki
Takahiro Seki
CFCarina Fischer
Carina Fischer
ODOlivier Dubey
Olivier Dubey
Yihai CaoYihai Cao
Yihai Cao
Vascular pericytes, an important cellular component in the tumor microenvironment, are often associated with tumor vasculatures, and their functions in cancer invasion and metastasis are poorly understood. Here we show that PDGF-BB induces pericyte–fibroblast transition (PFT), which significantly contributes to tumor invasion and metastasis. Gain- and loss-of-function experiments demonstrate that PDGF-BB-PDGFRβ signaling promotes PFT both in vitro and in in vivo tumors. Genome-wide expression analysis indicates that PDGF-BB–activated pericytes acquire mesenchymal progenitor features. Pharmacological inhibition and genetic deletion of PDGFRβ ablate the PDGF-BB–induced PFT. Genetic tracing of pericytes with two independent mouse strains, TN-AP-CreERT2:R26R-tdTomato and NG2-CreERT2:R26R-tdTomato, shows that PFT cells gain stromal fibroblast and myofibroblast markers in tumors. Importantly, coimplantation of PFT cells with less-invasive tumor cells in mice markedly promotes tumor dissemination and invasion, leading to an increased number of circulating tumor cells and metastasis. Our findings reveal a mechanism of vascular pericytes in PDGF-BB–promoted cancer invasion and metastasis by inducing PFT, and thus targeting PFT may offer a new treatment option of cancer metastasis. Significance We show that vascular pericytes significantly contribute to cancer invasion and metastasis by the mechanism of the pericyte–fibroblast transition (PFT). This study proposes this concept and indicates the vascular pericyte’s role. Vascular pericytes were considered to remodel tumor vessels toward a mature phenotype. However, once dissociated from tumor vessels their functions within the tumor tissue are not known. In the present study, we show that pericytes, once detached from tumor microvasculatures, underwent differentiation to become stromal fibroblasts, which are known to contribute to tumor invasion and metastasis. Our results show that vascular pericytes are the important source of stromal fibroblasts and targeting PFT may offer a new treatment option in cancer metastasis.

1 July 2018 in Cell Metabolism
Verified
Journal Article
Closed access
HIHideki Iwamoto
Hideki Iwamoto
MAMitsuhiko Abe
Mitsuhiko Abe
YYYunlong Yang
Yunlong Yang
DCDongmei Cui
Dongmei Cui
TSTakahiro Seki
Takahiro Seki
Yihai CaoYihai Cao
Yihai Cao

3 August 2022 in Nature
Verified
Journal Article
Open access
PDF file
TSTakahiro Seki
Takahiro Seki
YYYunlong Yang
Yunlong Yang
XSXiaoting Sun
Xiaoting Sun
SLSharon Lim
Sharon Lim
SXSisi Xie
Sisi Xie
Yihai CaoYihai Cao
Yihai Cao
Glucose uptake is essential for cancer glycolysis and is involved in non-shivering thermogenesis of adipose tissues1–6. Most cancers use glycolysis to harness energy for their infinite growth, invasion and metastasis2,7,8. Activation of thermogenic metabolism in brown adipose tissue (BAT) by cold and drugs instigates blood glucose uptake in adipocytes4,5,9. However, the functional effects of the global metabolic changes associated with BAT activation on tumour growth are unclear. Here we show that exposure of tumour-bearing mice to cold conditions markedly inhibits the growth of various types of solid tumours, including clinically untreatable cancers such as pancreatic cancers. Mechanistically, cold-induced BAT activation substantially decreases blood glucose and impedes the glycolysis-based metabolism in cancer cells. The removal of BAT and feeding on a high-glucose diet under cold exposure restore tumour growth, and genetic deletion of Ucp1—the key mediator for BAT-thermogenesis—ablates the cold-triggered anticancer effect. In a pilot human study, mild cold exposure activates a substantial amount of BAT in both healthy humans and a patient with cancer with mitigated glucose uptake in the tumour tissue. These findings provide a previously undescribed concept and paradigm for cancer therapy that uses a simple and effective approach. We anticipate that cold exposure and activation of BAT through any other approach, such as drugs and devices either alone or in combination with other anticancer therapeutics, will provide a general approach for the effective treatment of various cancers.

1 March 2012 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
SLSharon Lim
Sharon Lim
JHJennifer Honek
Jennifer Honek
YXYuan Xue
Yuan Xue
TSTakahiro Seki
Takahiro Seki
ZCZiquan Cao
Ziquan Cao
Yihai CaoYihai Cao
Yihai Cao